CUE News and Press, Cue Biopharma Inc. From 03/04/22

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...

CAMBRIDGE, Mass., March 02, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient’s body, ann...

CUE has been in the market since 2014, and they still haven't completed a phase 1 trial. They plan to announce topline phase 1 data in July. The company is very low in cash. For further details see: Cue Biopharma: Too Long To Arrive At Topline Trial Data

Presentation provides mechanistic insights and progress update on collaboration with the laboratory of Michael Dustin at the University of Oxford to study the role of IL-2 in the T cell immunological synapse formation using the IL-2 based CUE-100 series CAMBRIDGE, Mass., Feb. 15, ...

Early data in the combination study of CUE-101 and KEYTRUDA® (pembrolizumab) supports synergistic activity; of four patients treated in dose escalation in the 2mg/kg and RP2D 4mg/kg cohorts, two have partial responses (1 confirmed and 1 unconfirmed) and two are manifesting redu...

CAMBRIDGE, Mass., Jan. 20, 2022 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient’s body, ann...

Selective activation and expansion of Wilms’ Tumor 1 ( WT1)-specific cytotoxic CD8+ T cells in preclinical models supports the potential for clinical activity treating WT1-expressing cancers Further advancement of CUE-102 enhances pipeline development and ...

Fourth vaccine: Israel is set to become the first country in the world to administer a fourth COVID-19 vaccine, which would give "greater protection in the face of Omicron." The first eligible group to receive the vaccine will be people age 60 and older, as well as the immunocompromised and m...

As COVID cases are surging and along with it a resurgence in the demand for testing, test makers are mixed so far today. Quidel (QDEL -5.8%), a largest manufacturers of at-home tests, is the worst performer of the group. OraSure Technologies (OSUR -3.1%), another at-home test maker, is also d...

New York City Mayor Bill de Blasio this afternoon said that the city will be distributing 500K rapid at-home COVID tests and 1M KN95 masks in the latest effort to curb the spread of the virus. The city is also increasing testing capacity by increasing hours at sites and adding more of them. I...